Sonoma Pharmaceuticals Announces FDA Approval for Antimicrobial Post-Therapy Gel
05 avr. 2018 07h05 HE
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., April 05, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective...
Sonoma Pharmaceuticals Introduces New and Improved Acuicyn™ Antimicrobial Eyelid and Eyelash Hygiene Solution
27 mars 2018 07h05 HE
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., March 27, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective...
Sonoma Pharmaceuticals to Present at Roth Capital Partners 30th Annual Growth Stock Conference on March 13, 2018
09 mars 2018 07h05 HE
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., March 09, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA, Warrants – SNOAW) today announced that Jim Schutz, Sonoma CEO, will be a featured presenter at the...
Sonoma Pharmaceuticals Announces Closing of $5 Million Public Offering of Common Stock
06 mars 2018 19h27 HE
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, Warrants – SNOAW) today announced the closing of a public offering of 1,428,570 shares of common...
Sonoma Pharmaceuticals Announces Pricing of $5 Million Public Offering of Common Stock
02 mars 2018 08h00 HE
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., March 02, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, Warrants – SNOAW) today announced the pricing of a “best efforts” public offering of up to 1,428,571...
Sonoma Pharmaceuticals Reports Record Total Revenue of $4.8 million for Third Quarter FY 2018 with Year over Year Product Revenue Growth of 46%
07 févr. 2018 16h05 HE
|
Sonoma Pharmaceuticals, Inc.
Product revenue up 12% compared to September 2017 quarterU.S. product revenue up 27% compared to the September 2017 quarterCash on hand equals $8.6 million at quarter end Conference Call Begins at...
Sonoma Pharmaceuticals Announces Fiscal Third Quarter 2018 Financial Results and Conference Call
25 janv. 2018 07h05 HE
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW) today announced that financial results for its fiscal third quarter 2018, ended...
Sonoma Pharmaceuticals Receives Three New United Arab Emirates Regulatory Approvals: Acuicyn® for Management of Blepharitis, Microsafe® Oral Care for Mucositis and Sinudox® for Chronic Sinusitis
09 janv. 2018 07h05 HE
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., Jan. 09, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective...
Sonoma Pharmaceuticals Announces Second FDA Approval to Add Antimicrobial Language to Alevicyn™ Gel Products for Management of Atopic Dermatitis
05 déc. 2017 07h05 HE
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective...
Sonoma Pharmaceuticals Announces FDA Approval of Expanded Indication for Alevicyn™ to Add Antimicrobial Language
16 nov. 2017 07h45 HE
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective...